Get caught up on CMS proposals for Part D networks, mail order and price negotiations
In January, the Centers for Medicare and Medicaid Services (CMS) detailed potential new rules for Part D. Here’s the least you need to know about the proposed changes.
Currently: The Medicare Modernization Act (MMA) has a statue that prohibits the Department of Health and Human Services (HHS) from intervening with the market negotiations that occur between plans and pharmacies and drug manufacturers. Additionally, MMA does not permit a specific price structure for Part D reimbursement.
Proposed: The proposal changes the interpretation of MMA to permit Washington involvement in the pharmacy and plan sponsor price negotiations, rather than allowing plans to leverage volume for optimal pricing.
Currently: Plans are using preferred networks to funnel beneficiaries toward high-value pharmacies.
Proposed: CMS proposes an “any willing pharmacy” requirement so plan sponsors would be obligated to contract with any pharmacy that wants to participate. CMS says the rule is meant to allow for wider networks and more choice for seniors. According to Drug Channels Institute, the average premium for a basic prescription drug plan with a preferred network in 2014 is 21% lower than the average premium for a plan that does not use a preferred network.
Currently: Networks often use or own a mail-order pharmacy, which is required to ensure patient approval before shipping medication. Orders cannot be shipped automatically. According to CMS, the typical standard for delivery time is seven to 10 days.
Proposed: CMS would create new requirements for shipment of medication within three days (for straightforward fills) or five days (if provider interaction or prior authorization is needed). Obtaining patient acknowledgement could delay the shipping date and cause the pharmacy to fail to meet the three or five day requirement.
NEXT >> Number of Plans
Currently: There are 1,169 Part D plans in 2014, according to the Kaiser Family Foundation.
Proposed: CMS would limit each issuer to offering one enhanced plan and one standard plan in each of the 34 Part D regions in 2016. The rule would result in plan consolidation and fewer choices.
Sources: American Action Forum, Kaiser Family Foundation, Drug Channels Institute
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Medicare’s Drug Negotiation Could Lead to Greater Access — or More Utilization Management
October 3rd 2023Even though the Inflation Reduction Act will require plans to justify formulary placement of negotiated drugs, payers have more of an incentive to steer patients to lower-cost alternatives.
Read More